Medical/Pharmaceuticals

United Imaging Ramps Up U.S. Hiring, Opens a Seattle Office

The company continues to build strength in the U.S. market, already present in 35 states in its sixth year. HOUSTON, Feb. 12, 2024 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, is off to a fast start again in 2024, with 71 o...

2024-02-12 23:00 1657

E-Home Household Services Holdings Limited's subsidiary Zhongrun Pharmaceutical intends to acquire NBL (New Zealand) Limited to help expand the international market

FUZHOU, China, Feb. 8, 2024 /PRNewswire/ -- E-Home Household Services Holdings Limited (NASDAQ:EJH) (the "Company" or "eHome"), an integrated home services provider inChina, announced that its subsidiary, Zhongrun (Fujian) Pharmaceutical Co., Ltd, intends to acquire NBL (New Zealand) Limited ("NB...

2024-02-08 22:00 4904

MGI Named a Finalist in the 2024 Edison Awards™ for Innovative DNBSEQ-T20x2* Gene Sequencer

SHENZHEN, China, Feb. 8, 2024 /PRNewswire/ -- MGI Tech , a company committed to building core tools and technology to lead life science, today announced its nomination as a finalist for the2024 Edison Awards™  in the "Health, Medical ...

2024-02-08 21:00 1754

First in Human Dosed in Clinical Trial of ZMA001 for Treatment of Pulmonary Arterial Hypertension (PAH)

INCHEON, South Korea, Feb. 7, 2024 /PRNewswire/ -- Zymedi announced today that the first in human dosage of ZMA001, a monoclonal antibody being developed as a first-in-class treatment for Pulmonary Arterial Hypertension (PAH) has been initiated. The placebo-controlled phase 1 trial designed to a...

2024-02-08 11:53 1559

Datasea Regains Compliance with NASDAQ Minimum Bid Price Requirement

BEIJING, Feb. 7, 2024 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada incorporated digital technology corporation engaged in innovative business segments for intelligent acoustics and 5G messaging technology inChina announced today that, on February 6, 2024, it ...

2024-02-07 22:15 4153

Complete Genomics and seqWell Announce Codevelopment Partnership at AGBT

Companies will work together to offer fast, cost-effective ultra-high-throughput library preparation workflows SAN JOSE, Calif. and BEVERLY, Mass., Feb. 7, 2024 /PRNewswire/ -- Complete Genomics, a life sciences company specializing in end-to-end DNA sequencin...

2024-02-07 22:00 1770

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

* Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech  * Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncology clinical assets and builds shareholder value by streamlining the operating model, reduc...

2024-02-07 19:00 1645

GC Labs successfully concludes day2 of Medlab Middle East 2024

YONGIN, South Korea, Feb. 6, 2024 /PRNewswire/ -- GC Labs, a leading clinical laboratory inSouth Korea, announced that the company concluded day2 with a successful performance at the Medlab Middle East 2024. An image o...

2024-02-06 23:00 1710

At AGBT, Complete Genomics showcases expanded sequencing applications, talks from customers and collaborators on research powered by the DNBSEQ-T7 Sequencer

The genomic sequencing solutions provider also introduces Q40 sequencing quality, announces new DNBSEQ products SAN JOSE, Calif., Feb. 6, 2024 /PRNewswire/ -- Complete Genomics, a California-based life sciences company that provides novel, comprehensive sequen...

2024-02-06 22:00 1484

Rokit Healthcare Scores High Marks in KOSDAQ Tech Listing Evaluation

SEOUL, South Korea, Feb. 5, 2024 /PRNewswire/ -- Rokit Healthcare, a trailblazer in AI-driven medical bioprinting technology, proudly announces its achievement of an AA rating in the KOSDAQ (Korea Securities Dealers Automated Quotations) technology listing evaluation. Garnering A grades from both...

2024-02-05 22:00 2040

Genesis MedTech Completes Enrollment in its United States Early Feasibility Study Utilizing the J-Valve™ Transfemoral System for Patients with Severe Aortic Regurgitation

JC Medical reports milestone accomplishment with its TAVR device BURLINGAME, Calif., Feb. 5, 2024 /PRNewswire/ -- Genesis MedTech, a leading medical device company, today announced the completion of enrollment in its United States Early Feasibility Study (EFS) using its dedicated transcatheter ...

2024-02-05 22:00 1421

BrainGear Develops SleePYA, the Digital Healthcare for Brain Rehabilitation and Sleep Aid

SEOUL, South Korea, Feb. 5, 2024 /PRNewswire/ -- As startup engaging in digital healthcare business, especially brain rehabilitation and sleep aid, BrainGear has developed SleePYA with infrared light to stimulate the brain to induce quality of sleep.

2024-02-05 22:00 1510

Technoderma Medicines Phase 2 Clinical Trial of TDM-105795 Demonstrates Hair Growth in Androgenetic Alopecia

CHENGDU, China, Feb. 5, 2024 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed its Phase 2a clinical trial (NCT05802173) of TDM-105795 topical solution for Androgenetic Alopecia (AGA). This ...

2024-02-05 21:00 1504

NouvNeu001 Achieves Milestone with Successful Dosing of First Patient, Signaling Smooth Progress in iRegene Therapeutics' Multicenter Clinical Trial for Innovative Novel Parkinson's Disease Therapy

WUHAN, China, Feb. 5, 2024 /PRNewswire/ -- iRegene Therapeutics Co., Ltd (iRegene) recently announced that NouvNeu001, the company's first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the patient has also successfully concluded the observation per...

2024-02-05 21:00 1737

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy

* ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. * Phase 1 Clinical Study Expected to Begin in H2 2024. ALAMEDA, Calif. and TAIPEI, Feb. 4, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical stag...

2024-02-05 08:00 1487

Blossoming Flowers at the Top of the Biopharmaceutical Tree -- Reflections on the Flourishing of Sanyou's 4C Business

SHANGHAI, Feb. 2, 2024 /PRNewswire/ -- In 1996, MDS Pharma Service invested in and established the first true Contract Research Organization (CRO) inChina, dedicated to clinical trial business for new drugs. This marked the official launch of the CRO industry inChina. The concept of CRO originat...

2024-02-03 08:00 2438

Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED

* Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor * Inmagene retains rights to develop and commerciali...

2024-02-02 22:00 2215

2024 Global Appeal Calls for Well-Informed Public to 'Break Chains of Discrimination' against Leprosy

TOKYO, Feb. 1, 2024 /PRNewswire/ -- Sasakawa Leprosy (Hansen's Disease) Initiative has partnered with the World Health Organization to co-host the launch of the 2024 Global Appeal to end stigma and discrimination against persons affected by leprosy at WHO headquarters inGeneva on January 31, 2024...

2024-02-01 14:00 1619

Promising Clinical Results on the World's First Use of BCMA CAR-T to Treat Immune Mediated Necrotizing Myopathy (IMNM) Published on the Proceedings of the National Academy of Sciences (PNAS)

SHANGHAI, NANJING, China and SAN JOSE, Calif., Jan. 31, 2024 /PRNewswire/ -- On Jan. 30, 2024, PNAS published the research paper titled "Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR T-cell therapy." The paper analyzed results using the fully human B ...

2024-02-01 11:07 1931

Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development

TAIPEI, Jan. 31, 2024 /PRNewswire/ -- Anbogen Therapeutics, a clinical-stage biotechnology company specializing in groundbreaking cancer drug development, today announced the successful completion of its Series A funding round. The lead investor is China Development Industrial Bank (CDIB), with s...

2024-02-01 00:00 1652
1 ... 39404142434445 ... 214

Week's Top Stories